Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge |
| |
| Institution: | 1. Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, USA;2. Institut für Funktionelle Genomforschung der Mikroorganismen, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany;1. Department of Anatomy, Histology and Embriology, University of Split School of Medicine, ?oltanska 2, 21000 Split, Croatia;2. Department of Animal Nutrition and Dietetics, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia;1. WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, VIC 3000, Australia;2. Department of Infectious Diseases/Infection Prevention, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000, Australia;3. Fielding School of Public Health, University of California, Los Angeles, USA;4. School of Population and Global Health, University of Melbourne, Melbourne, Australia;1. Departamento de Matemáticas, Centro de Investigación de Física Teórica y Matemática FIMAT, University of Huelva, 21071 Huelva, Spain;2. Departamento de Matemática Aplicada II, E.S. Ingenieros, University of Sevilla, Camino de los Descubrimientos s/n, 41092 Sevilla, Spain;1. Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA;2. Etubics Corporation, 41 West Harrison Street, Suite 100, Seattle, WA 98119, USA |
| |
| Abstract: | ObjectivesTo test vaccines, formulated with novel antigens, to protect mice against Chlamydia infections.MethodsTo determine the ability of polymorphic membrane proteins (Pmps) to induce cross-species protective immune responses, recombinant fragments from all nine C. trachomatis serovar E Pmps were used to vaccinate BALB/c mice utilizing CpG-1826 and Montanide ISA 720 as adjuvants. C. muridarum recombinant MOMP and PBS, formulated with the same adjuvants, were used as positive and negative controls, respectively. Mice were challenged intranasally with 104 inclusion-forming units (IFU) of C. muridarum. Animals were weighed daily and at 10 days post-challenge, they were euthanized, their lungs harvested, weighed and the number of chlamydial IFU counted.ResultsFollowing vaccination the nine Pmps elicited immune responses. Based on body weight changes, or number of IFU recovered from lungs, mice vaccinated with Pmp C, G or H were the best protected. For example, over the 10-day period, the negative control group vaccinated with PBS lost significantly more body weight than mice immunized with PmpC or G (P < 0.05). C. muridarum MOMP vaccinated mice were better protected against body weight losses than any group immunized with Pmps. Also, the median number of IFU recovered from the lungs of mice vaccinated with PmpC (72 × 106) or PmpH (61 × 106) was significantly less than from mice immunized with PBS (620 × 106; P < 0.05). As determined by the number of IFU, all Pmps elicited less protection than C. muridarum MOMP (0.078 × 106 IFU; P < 0.05).ConclusionsThis is the first time PmpC has been shown to elicit cross-species protection against a respiratory challenge. Additional work with Pmps C, G and H is recommended to determine their ability to protect animal models against genital and ocular challenges. |
| |
| Keywords: | Polymorphic membrane proteins (Pmps) Vaccine PmpC |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
